Cornell R C, Greenway H T, Tucker S B, Edwards L, Ashworth S, Vance J C, Tanner D J, Taylor E L, Smiles K A, Peets E A
Division of Dermatology and Cutaneous Surgery, Scripps Clinic and Research Foundation, La Jolla, CA 92037.
J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700. doi: 10.1016/0190-9622(90)70276-n.
In a clinical trial of 172 patients at four medical centers, interferon alfa-2b (1.5 x 10(6) IU) or a placebo was injected directly into biopsy-proved noduloulcerative or superficial basal cell carcinomas three times weekly for 3 weeks, for a cumulative dose of 13.5 million IU. Efficacy of treatment was determined at 16 to 20 weeks by examination of biopsy specimens that demonstrated cure of lesions in 86% of interferon-treated patients and in only 29% of placebo-treated patients. During the treatment course and follow-up, an initial inflammatory response was observed at the treatment sites, followed by diminished erythema, improvement in overall appearance, and a decrease in size of lesions. Side effects of treatment, mainly flu-like symptoms, were usually mild and transient and occurred more commonly in the interferon-treated group. Only three patients, all in the interferon-treated group, discontinued therapy because of side effects. One year after initiation of therapy, 81% of interferon recipients and 20% of those given the placebo remained tumor free. Noduloulcerative and superficial lesions were equally responsive to treatment with interferon. For some patients with noduloulcerative or superficial basal cell carcinomas, intralesional interferon alfa-2b may be an alternative, effective treatment.
在四个医疗中心对172例患者进行的一项临床试验中，将干扰素α-2b（1.5×10⁶国际单位）或安慰剂每周三次直接注射到经活检证实的结节溃疡性或浅表性基底细胞癌中，持续3周，累积剂量为1350万国际单位。在16至20周时，通过检查活检标本确定治疗效果，结果显示86%接受干扰素治疗的患者病变治愈，而接受安慰剂治疗的患者中只有29%病变治愈。在治疗过程和随访期间，在治疗部位观察到最初的炎症反应，随后红斑减轻、整体外观改善且病变大小减小。治疗的副作用主要为类流感症状，通常较轻且为一过性，在接受干扰素治疗的组中更常见。只有三名患者（均在接受干扰素治疗的组中）因副作用而停止治疗。治疗开始一年后，81%接受干扰素治疗的患者和20%接受安慰剂治疗的患者仍无肿瘤。结节溃疡性和浅表性病变对干扰素治疗的反应相同。对于一些结节溃疡性或浅表性基底细胞癌患者，病灶内注射干扰素α-2b可能是一种有效的替代治疗方法。
